Skip to content
Screener

AbCellera Biologics Inc. ABCL Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$9.0MBeat by $2.6M
EPS-$0.19Miss by $0.02
Revenue estimate$6.3M
EPS estimate-$0.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q3 2025

Income statement

See full
Revenue$9.0M+37.6%
Operating income-$76.3M+18.6%
Net income-$57.1M-11.8%
EPS (diluted)-$0.19-11.8%

Balance sheet

See full
Cash & equivalents$108.2M-28.7%
Total debt$142.2M+99.2%
Total equity$964.0M-10.6%
Total assets$1.4B-2.6%

Cash flow

See full
Operating cash flow-$52.6M-82.1%
CapEx$8.9M-51.8%
Free cash flow-$61.5M-29.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.5B+96.2%
Enterprise value$1.54B+124%
P/S42.6×+19.3×

Profitability

See full
Operating margin-739.7%-128pp
Net margin-486%-39.6pp
FCF margin-433.4%-93.8pp

Returns & leverage

See full
Return on equity-16.8%+1.5pp
Debt / equity0.1×+0.1×
Current ratio10.1×+0.8×

Segments

By geography

See full
Canada$16.0M+144%
United States$2.8M+311%

By product

See full
Research fees$8.8M+40.2%

FAQ

When did AbCellera Biologics Inc. report Q3 2025 earnings?
AbCellera Biologics Inc. (ABCL) reported Q3 2025 earnings on November 6, 2025 after market close.
What were AbCellera Biologics Inc.'s Q3 2025 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $9.0M and eps of $-0.19 for Q3 2025.
Did AbCellera Biologics Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $6.3M by $2.6M. EPS missed the consensus estimate of $-0.17 by $0.02.
How did AbCellera Biologics Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.6% from $6.5M a year earlier and eps declined 11.8% from $-0.17.
Where can I find AbCellera Biologics Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001703057-25-000024) and the 10-Q periodic report (0001703057-25-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.